Dose-Finding Study of Bixalomer in Patients With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia: A Double-Blind, Randomized, Placebo-Controlled and Sevelamer Hydrochloride-Controlled Open-Label, Parallel Group Study

• Published in: Therapeutic apheresis and dialysis Vol. 18; no. S2; pp. 24 - 32
• Main Authors: Akizawa, Tadao, Origasa, Hideki, Kameoka, Chisato, Kaneko, Yuichiro, Kanoh, Hiroyuki
• Format: Journal Article
• Language: English
• Published: Australia Blackwell Publishing Ltd 01.06.2014
• Subjects: Bixalomer; Chelating Agents - therapeutic use; Dose-finding; Dose-Response Relationship, Drug; Double-Blind Method; Hemodialysis; Hyperphosphatemia; Hyperphosphatemia - blood; Hyperphosphatemia - drug therapy; Hyperphosphatemia - etiology; Japan; Kidney disease; Phosphorus - blood; Polyamines - blood; Polyamines - therapeutic use; Randomized controlled trial; Renal Dialysis - adverse effects; Renal Insufficiency, Chronic - blood; Renal Insufficiency, Chronic - therapy; Sevelamer; Treatment Outcome; Japan; Bixalomer; Kidney disease; Dose-finding; Hyperphosphatemia; Hemodialysis; Randomized controlled trial

Hyperphosphatemia is a prognostic factor for morbidity and mortality in chronic kidney disease. Bixalomer (Kiklin® Capsules) is a non‐absorbable polymer that decreases serum phosphate levels by binding phosphate in the gastrointestinal tract. This study was a multicenter, double‐blind, randomized, p...